The UT M. D. Anderson Cancer Center (MDACC) joined the Southwest Oncology Group (SWOG) as a full member in November 2002. This is our first U10 member application. During the past 3 years and entirely prior to becoming a full SWOG member, MDACC averaged 51 accruals to SWOG therapy studies per year. Our SWOG Program will integrate many elements of MDACCs comprehensive multidisciplinary resources, including 16 specialized Care Centers, where most MDACC patients are treated as outpatients in a multidisciplinary, multimodality team approach. MDACC has 895 cancer research faculty, including 536 clinical faculty. In 2001, MDACC cared for 62,600 cancer patients, of whom 16,144 were newly diagnosed and 3,500 were enrolled in therapeutic protocols. The structure for coordinating SWOG studies includes the Principal Investigator, Co-Principal Investigator, Head CRA, SWOG Program Steering Committee, and leaders of each disease-site program (medical oncologists, radiotherapists, surgeons). Every MDACC-SWOG Program disease-site leader is a MDACC department chair sitting on the Executive Council of the Division of Cancer Medicine headed by Dr. Waun Ki Hong, who enthusiastically supports SWOG therapy/accrual activities within MDACC. Substantial MDACC administrative contributions to SWOG in the past 6 years include Chair, Cancer Control Research Committee and member, SWOG Executive Committee/Scientific Advisory Board (Dr. Lippman); Chair, Gastrointestinal Committee (Dr. Abbruzzese); Co-Chair, Brain Committee (Dr. Sawaya); Vice Chair, Lung Developmental Therapeutics Committee (Dr. Herbst); Chair, Testis Subcommittee (Dr. Logothetis); and Vice Chair, Sarcoma (Special Populations) Committee (Dr. Bleyer). At least 21 MDACC faculty are official members of SWOG and contribute actively to several SWOG committees on a regular basis (e.g., the Gastrointestinal, Brain, Lung, H & N, and Sarcoma committees). Dr. EI-Naggar will head the SWOG H&N Tumor Biology and Correlative Science Subcommittee. Dr. P. Pisters is a consultant for the SWOG Sarcoma Specimen Board. At least 11 MDACC faculty provided scientific leadership as Study Coordinators in 17 SWOG-coordinated protocols (including 3 in development) and co-authored 18 SWOG papers (since 2000). MDACC will apply its historical strengths in developing innovative Phase I, II studies within the SWOG setting. Phase III trials are highly complex and difficult for any single institution to conduct alone, and MDACC looks forward to leading some and joining other SWOG efforts to test novel approaches in Phase Ill, standard-of-care-altering trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA105409-04
Application #
7219501
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
2004-07-26
Project End
2009-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
4
Fiscal Year
2007
Total Cost
$229,230
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Haas, Naomi B; Manola, Judith; Dutcher, Janice P et al. (2017) Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol 3:1249-1252
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Herbst, Roy S; Gandara, David R; Hirsch, Fred R et al. (2015) Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21:1514-24
Walter, Roland B; Othus, Megan; Löwenberg, Bob et al. (2015) Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica 100:e409-11
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Walter, R B; Othus, M; Burnett, A K et al. (2015) Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29:312-20
Haas, Naomi B; Manola, Judith; Ky, Bonnie et al. (2015) Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res 21:4048-54
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 38 publications